Exon Skipping Therapies Market Anticipated To Reach $5.89 Billion By 2030 With 20.4% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Exon Skipping Therapies Market Grow Between 2026 And 2030?
The exon skipping therapies market has experienced significant expansion in recent times. This market is set to increase from $2.34 billion in 2025 to $2.81 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 20.1%. The growth observed in the past can be attributed to various factors such as the increasing occurrence of Duchenne muscular dystrophy, advancing research into RNA splicing mechanisms, prompt regulatory approvals for antisense therapies, growing financial support for rare disease investigations, and an expansion of biotechnology partnerships.
The exon skipping therapies market is anticipated to experience substantial growth over the coming years. This market is projected to reach $5.9 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.4%. Factors driving this expansion during the forecast period encompass the increasing acceptance of personalized genetic medicine, a growing number of exon-targeted therapies in development, enhanced investment in sophisticated delivery systems, a wider range of approvals for inherited neuromuscular disorders, and strengthened partnerships between research institutions and biopharmaceutical firms. Key trends anticipated during the same period involve progress in antisense oligonucleotide chemistry, a heightened emphasis on rare genetic disorders, the broadening of combination genetic therapy strategies, increasing capital allocation towards RNA-based therapeutics pipelines, and an uptick in clinical trials targeting exon-specific mutations.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Drivers Are Fueling The Growth Of The Exon Skipping Therapies Market?
The increasing occurrence of genetic disorders is anticipated to propel the expansion of the exon skipping therapies market throughout the forecast period. Genetic disorders refer to conditions arising from irregularities in an individual’s genetic material (DNA), including single-gene mutations and chromosomal alterations that can lead to inherited or acquired diseases. The observable rise in the prevalence of genetic disorders is largely attributable to advancements in diagnostic technologies and the expanding utilization of genetic testing and newborn screening programs, which facilitate earlier and more precise identification of previously undiagnosed cases. Exon skipping therapies are formulated to address specific genetic mutations by selectively excluding faulty exons during messenger RNA (mRNA) processing, thus restoring the production of partially or fully functional proteins. This targeted therapeutic strategy directly tackles the underlying molecular causes of certain genetic disorders, particularly rare and formerly untreatable conditions, garnering significant clinical and commercial interest. For instance, in October 2024, according to the National Health Service (NHS) England, a UK-based government department, a groundbreaking newborn screening initiative commenced across NHS hospitals to test hundreds of newborns for more than 200 rare genetic conditions, with plans to extend screening to up to 100,000 babies across England. Hence, the rising prevalence of genetic disorders is driving the growth of the exon skipping therapies market.
How Is The Exon Skipping Therapies Market Organized By Segment Classification?
The exon skipping therapies market covered in this report is segmented –
1) By Product Type: Antisense Oligonucleotides, Synthetic Ribonucleic Acid Molecules, Exon-Targeted Gene Therapy Kits, Combination Therapy Formulations, Other Product Types
2) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Route Of Administration
3) By Distribution Channel: Direct Sales, Distributors, Online Pharmacies, Other Distribution Channel
4) By Application: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy, Other Inherited Diseases, Other Applications
5) By End-User: Hospitals And Clinics, Research Institutes, Biopharmaceutical Companies, Specialty Genetic Centers, Other End Users
Subsegments:
1) By Antisense Oligonucleotides: Phosphorodiamidate Morpholino Oligonucleotides, Peptide Conjugated Oligonucleotides, Gapmer Oligonucleotides, Steric Blocking Oligonucleotides, Splice Modulating Oligonucleotides
2) By Synthetic Ribonucleic Acid Molecules: Messenger Ribonucleic Acid Molecules, Small Interfering Ribonucleic Acid Molecules, Guide Ribonucleic Acid Molecules, Modified Ribonucleic Acid Molecules, Therapeutic Ribonucleic Acid Constructs
3) By Exon-Targeted Gene Therapy Kits: Viral Vector Delivery Kits, Non-Viral Delivery Kits, Plasmid-Based Gene Therapy Kits, Targeted Editing Delivery Kits, Tissue Specific Delivery Kits
4) By Combination Therapy Formulations: Gene Therapy And Drug Combination, Oligonucleotide And Small Molecule Combination, Multi-Target Genetic Therapy, Supportive Protein Therapy Combination, Sequential Genetic Therapy Formulations
5) By Other Product Types: Peptide Based Genetic Modulators, Nanoparticle Delivery Formulations, Lipid Based Delivery Systems, Targeted Molecular Complexes, Personalized Genetic Therapy Formats
What Trends Are Influencing The Exon Skipping Therapies Market?
Leading firms within the exon skipping therapies market are progressively prioritizing the creation of novel therapeutic approaches, including experimental antibody-oligonucleotide conjugate (AOC) therapies, aimed at optimizing targeted delivery and boosting dystrophin synthesis in individuals suffering from Duchenne muscular dystrophy (DMD). AOC therapies signify an advanced method that unites a monoclonal antibody with a synthetic oligonucleotide, thereby facilitating the precise delivery of exon-skipping molecules straight into muscle cells. As an illustration, in July 2025, Avidity Biosciences Inc., a biotechnology firm based in the U.S., was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for delpacibart zotadirsen (del-zota), an experimental AOC therapy designed for managing DMD in patients whose mutations are suitable for exon 44 skipping. Del-zota is composed of a unique monoclonal antibody linked to phosphorodiamidate morpholino oligomers (PMOs), which encourage exon 44 skipping during the mRNA processing phase. This treatment is presently undergoing Phase 2 clinical development, with intentions for regulatory submission to be backed by strong biomarker and clinical efficacy data. These progress points emphasize the increasing focus on distinct delivery platforms within the exon skipping therapies market and demonstrate how AOC technologies are influencing the trajectory of precision therapies for inherited neuromuscular conditions.
Who Are The Industry Participants Involved In The Exon Skipping Therapies Market?
Major companies operating in the exon skipping therapies market are Daiichi Sankyo Company Limited, BioMarin Pharmaceutical Inc., Sarepta Therapeutics, Nippon Shinyaku Co. Ltd., Ionis Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals Inc., Entrada Therapeutics Inc., Wave Life Sciences, PepGen Inc., ProQR Therapeutics NV, NS Pharma Inc., Genethon, Astellas Gene Therapies, SQY Therapeutics, AUM Biotech Inc., Cure Rare Disease Inc., Autotelic Bio Inc., Dyne Therapeutics, Skip Therapeutics.
Get The Full Exon Skipping Therapies Market Report:
https://www.thebusinessresearchcompany.com/report/exon-skipping-therapies-market-report
Which Geographic Region Dominates The Exon Skipping Therapies Market?
North America was the largest region in the exon skipping therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exon skipping therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Exon Skipping Therapies Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Exon Skipping Therapies Market 2026, By The Business Research Company
adeno-associated virus (avv) vectors in gene therapy market report 2026
gastric cancer therapy market report 2026
https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report
over the counter (otc) drugs market report 2026
https://www.thebusinessresearchcompany.com/report/over-the-counter-otc-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
